Zhijuan Lin

1.4k total citations
49 papers, 935 citations indexed

About

Zhijuan Lin is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Zhijuan Lin has authored 49 papers receiving a total of 935 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 14 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Zhijuan Lin's work include Cancer-related molecular mechanisms research (10 papers), MicroRNA in disease regulation (8 papers) and RNA modifications and cancer (7 papers). Zhijuan Lin is often cited by papers focused on Cancer-related molecular mechanisms research (10 papers), MicroRNA in disease regulation (8 papers) and RNA modifications and cancer (7 papers). Zhijuan Lin collaborates with scholars based in China, United States and France. Zhijuan Lin's co-authors include Zhixia Zhou, Jianxun Wang, Xin Pang, Peifeng Li, Murugavel Ponnusamy, Xiang Ao, Peipei Shan, Bing Xu, Yuqi He and Elizabeth Vásquez and has published in prestigious journals such as Journal of Clinical Investigation, Blood and PLoS ONE.

In The Last Decade

Zhijuan Lin

44 papers receiving 929 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhijuan Lin China	18	508	334	214	155	73	49	935
Axelle Loriot Belgium	16	1.1k 2.2×	245 0.7×	223 1.0×	187 1.2×	61 0.8×	44	1.3k
Haimeng Yan China	12	541 1.1×	230 0.7×	314 1.5×	183 1.2×	35 0.5×	25	944
Jun Tan China	12	332 0.7×	201 0.6×	244 1.1×	63 0.4×	24 0.3×	33	800
Zhiming Cai China	16	426 0.8×	215 0.6×	86 0.4×	108 0.7×	37 0.5×	28	680
Michele Cummings United Kingdom	18	384 0.8×	171 0.5×	198 0.9×	290 1.9×	42 0.6×	36	933
Xia Luo China	15	367 0.7×	267 0.8×	447 2.1×	112 0.7×	37 0.5×	23	1.0k
Alexander M. Tseng United States	15	579 1.1×	267 0.8×	94 0.4×	125 0.8×	40 0.5×	27	946
Liubin Yang United States	13	917 1.8×	273 0.8×	180 0.8×	85 0.5×	43 0.6×	24	1.4k
Ebrahim Sakhinia Iran	22	681 1.3×	365 1.1×	184 0.9×	266 1.7×	243 3.3×	73	1.3k
Wei‐Yu Lin Taiwan	16	350 0.7×	116 0.3×	52 0.2×	123 0.8×	111 1.5×	44	667

Countries citing papers authored by Zhijuan Lin

Since Specialization

Citations

This map shows the geographic impact of Zhijuan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhijuan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhijuan Lin more than expected).

Fields of papers citing papers by Zhijuan Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhijuan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhijuan Lin. The network helps show where Zhijuan Lin may publish in the future.

Co-authorship network of co-authors of Zhijuan Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Zhijuan Lin. A scholar is included among the top collaborators of Zhijuan Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhijuan Lin. Zhijuan Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Z, Li, Hua Wang, Zhijuan Lin, et al.. (2025). Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial. Blood. 146(Supplement 1). 3580–3580.

Zhang, Lijie, et al.. (2025). Complicated crosstalk between HMGA and non-coding RNAs modulates hallmarks of cancer. Cancer Cell International. 25(1). 80–80.

Zhang, Yining, Yueting Huang, Hong Yan, et al.. (2024). Lactate acid promotes PD-1+ Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia. International Immunopharmacology. 130. 111765–111765. 15 indexed citations

Lai, Qian, Manman Deng, Zhijuan Lin, et al.. (2024). Resensitizing the Imatinib-Resistant Chronic Myeloid Leukemia through Reshaping the Glucose Mtabolism By Insulin Sensitizer. Blood. 144(Supplement 1). 5781–5781.

Liu, Long, Manman Deng, Qian Lai, et al.. (2024). Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma. Annals of Hematology. 103(10). 3839–3853. 3 indexed citations

Lin, Zhijuan, et al.. (2022). The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis. Critical Reviews in Oncology/Hematology. 176. 103756–103756. 7 indexed citations

Zhang, Lijie, et al.. (2022). Crosstalk among long non-coding RNA, tumor-associated macrophages and small extracellular vesicles in tumorigenesis and dissemination. Frontiers in Oncology. 12. 1008856–1008856. 7 indexed citations

Zhang, Wenjing, Zhijuan Lin, Fuyan Shi, et al.. (2022). HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer. Cancers. 14(14). 3495–3495. 9 indexed citations

Wang, Qiang, Zhijuan Lin, Zhuo Wang, et al.. (2021). RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 139(1). 59–72. 16 indexed citations

10.

Yuan, Chao, et al.. (2021). PIWI‑interacting RNA in cancer: Molecular mechanisms and possible clinical implications (Review). Oncology Reports. 46(3). 13 indexed citations

11.

Wu, Kangni, et al.. (2020). Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. International Immunopharmacology. 80. 106122–106122. 30 indexed citations

12.

Lin, Zhijuan, et al.. (2020). Association between obesity and the risk of uterine fibroids: a systematic review and meta-analysis. Journal of Epidemiology & Community Health. 75(2). 197–204. 42 indexed citations

13.

Ding, Dan, Xiang Ao, Mengyang Li, et al.. (2020). FOXO3a‐dependent Parkin regulates the development of gastric cancer by targeting ATP‐binding cassette transporter E1. Journal of Cellular Physiology. 236(4). 2740–2755. 17 indexed citations

14.

Zhou, Zhixia, Qiyong Gong, Zhijuan Lin, et al.. (2020). Emerging Roles of SRSF3 as a Therapeutic Target for Cancer. Frontiers in Oncology. 10. 577636–577636. 40 indexed citations

15.

Xu, Tao, Wei Ding, Xuejuan Zhang, et al.. (2019). miR-499-5p Attenuates Mitochondrial Fission and Cell Apoptosis via p21 in Doxorubicin Cardiotoxicity. Frontiers in Genetics. 9. 734–734. 55 indexed citations

16.

Lin, Yun, Zhijuan Lin, Li Z, et al.. (2018). The prognostic impact of long noncoding RNA HOTAIR in leukemia and lymphoma: a meta-analysis. Hematology. 23(9). 600–607. 10 indexed citations

17.

Zhou, Zhixia, Zhijuan Lin, Xin Pang, Peipei Shan, & Jianxun Wang. (2018). MicroRNA regulation of Toll-like receptor signaling pathways in teleost fish. Fish & Shellfish Immunology. 75. 32–40. 61 indexed citations

18.

Lin, Zhijuan, Xing Chen, Zhifeng Li, et al.. (2018). The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis. Annals of Hematology. 97(11). 2137–2144. 12 indexed citations

19.

Luo, Yiming, Tingbo Liu, Sili Wang, et al.. (2015). [Clinical features and risk factors for infections in adult acute leukemia after chemotherapy].. PubMed. 36(12). 1020–4. 1 indexed citations

20.

Tang, Jinbao, Hong‐Ming Yang, Baogang Zhang, et al.. (2013). Well-oriented ZZ–PS-tag with high Fc-binding onto polystyrene surface for controlled immobilization of capture antibodies. Analytica Chimica Acta. 776. 74–78. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact